Navigation Links
S*BIO Completes US$26 Million Equity Financing
Date:10/20/2008

SINGAPORE, Oct. 20 /PRNewswire/ -- S*BIO Pte Ltd, a cancer therapeutics company, today announced the completion of a US$26 million Series B financing led by Bio*One Capital and new investor Aravis Venture. Additional new investors included the Lacuna Apo BioTech Fund advised by Adamant Biomedical Investments AG and Zurcher Kantonalbank (ZKB). S*BIO will utilize the proceeds to primarily fund the development efforts of its two lead compounds, SB939, a HDAC inhibitor, and SB1518, a JAK 2 inhibitor, both in Phase 1 clinical trials.

"We have been successful in attracting some of the top biotech investors in this round and we highly appreciate their enthusiasm, continued support and strong belief in our pipeline," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "As part of the financing, we would like to welcome Jean-Philippe Tripet, Managing Partner of Aravis to our Board of Directors. Mr. Tripet, with his extensive knowledge and experience in the life sciences arena, is a valuable addition to the Board."

"This financing round is a recognition of the progress we have made in rapidly and effectively developing our compounds. We look forward to having our lead compounds tested in Singapore, U.S. and other international trial sites and advancing them further into Phase 2 development"

Ms. Swee Yeok Chu, CEO of Bio*One Capital said "S*BIO has made excellent progress in developing a proprietary pipeline of drug candidates with exciting profiles. The financing will allow the company to accelerate the clinical development of its promising anti-cancer agents."

About SB939

SB939 belongs to a new class of targeted anti-cancer therapeutics called histone deacetylase (HDAC) inhibitors. SB939 is designed to be a "best-in-class" therapeutic amongst HDAC inhibitors being developed worldwide, and has demonstrated the potential to bring additional therapeutic benefits due to its high potency, superior oral availability and good tolerability. SB939 is currently in Phase 1 clinical trials in both Singapore and Canada.

About SB1518

Currently in Phase 1 clinical trials in the U.S., SB1518 is a small molecule JAK2-selective kinase inhibitor which has high potency against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequencies in certain types of hematological disorders. By targeting the JAK2 activating mutation, SB1518 has the potential to interfere with a key mechanism driving the progress of a variety of cancers and other hematological disorders.

About Bio*One Capital

Bio*One Capital is a leading, dedicated biomedical sciences investment management company in Asia with a worldwide presence. Investments are focused on promising and innovative global biomedical companies where Bio*One Capital can play a value adding role in bridging and supporting companies' growth strategies in Asia through their operations in Singapore. A part of the Singapore Economic Development Board, Bio*One Capital oversees a portfolio of over 50 companies in US, Europe, Singapore and Asia. For more information, please visit http://www.bio1capital.com.

About Aravis Venture

Aravis Venture, founded in 2001, is an international venture capital group focusing on private biotech and renewable energy companies with presence in Cayman, Switzerland, Singapore and Menlo Park, California. The Aravis investment team is comprised of 13 partners, investment experienced leading scientists, venture capitalists and operating executives who have been involved with the successful financing, growth and realization of more than 80 companies worldwide over the last 20 years. With the combined know how of scientific/technical expertise and management, Aravis seeks to add value to its investments by actively participating in the buildup and growth of its portfolio companies. For more information, please visit http://www.aravis.ch.

About Adamant Biomedical Investments AG

The Lacuna Sicav - Lacuna Apo BioTech Fund is a Luxembourg-based healthcare fund investing in small and midcap biotech, medtech and specialty pharma companies world wide. The fund has received a AA-rating from S&P 5 times in a row since 2003. The fund is advised by Adamant Biomedical Investments AG, a specialized healthcare boutique focused on fund management of biotech, medtech and pharma funds. The team follows a fundamental bottom-up approach and consists of ten specialists with pharma, biotech and finance backgrounds. For more information, please visit http://www.adamantinvest.com.

About Zurcher Kantonalbank (ZKB)

Zurcher Kantonalbank (ZKB) is the leading universal bank in the Zurich region, focusing on both the national and, to a lesser extent, the international markets. With total assets of CHF 103.2 billion, it is the largest of the cantonal banks and the third largest bank in Switzerland. Building on its extensive expertise in the mortgage and credit businesses, it has developed very successfully into an investment and retirement-savings bank. ZKB is today one of the largest asset managers in Switzerland, with client assets of CHF 119 billion. As an independent institution incorporated under public law in the canton of Zurich, its activities are protected by government guarantee. Both Standard & Poor's and Moody's give ZKB's bonds and medium-term notes a top rating of AAA. For more information, please visit http://www.zkb.ch.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. Its second compound, SB1518, has also entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. A third compound, SB1317, is in pre-clinical development.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Novartis Bioventures and other international funds. More information about S*BIO can be found at http://www.sbio.com.

S*BIO Pte Ltd:

Stephen Keith Rhind, Ph.D.

Senior Vice President, Corporate Development

Tel: +65 6827 5000 (Singapore)

Stephen_rhind@sbio.com

Russo Partners:

Tony Russo +1 212-845-4251

Tony.Russo@russopartnersllc.com

Andreas Marathovouniotis +1 212-845-4253

Andreas.Marathis@russopartnersllc.com


'/>"/>
SOURCE S*BIO Pte Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
2. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
3. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Carrington Completes $8 Million Financing
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. New Brunswick Scientific Completes Merger Transaction with Eppendorf
8. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
9. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Companys Partner Completes Trial Production of a New Antiviral Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016 NX Prenatal Inc., a US ... technology for early warning of adverse pregnancy outcomes, ... study by Dr. Thomas McElrath of ... Fetal Medicine,s (SMFM) annual meeting held in ... 2016.  The presentation reported initial positive top-line results ...
(Date:2/10/2016)... Wash., Feb. 10, 2016  IsoRay, Inc. (NYSE MKT: ... brachytherapy and medical radioisotope applications for the treatment of ... today announced its financial results for the second quarter ... 31, 2015. --> ... quarter of fiscal 2016, which ended December 31, 2015, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, ... the promotion of two long-standing principal investigators (PI) to the roles of Chief ... and Development. , Dr. Laurence Chu, a Benchmark Research PI in the Austin ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... to their comprehensive training and support program, Sonalinkā„¢ remote monitoring. The inaugural launch ... performed on Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU technical ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016  BioMEMS devices deployed in ... on medical screening and diagnostic applications, such ... devices that facilitate and assure continuous monitoring ... are being bolstered through new opportunities offered ... acquisition coupled with wireless connectivity and low ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
(Date:2/1/2016)... Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ) announces the ... Joey Fatone . Las Vegas , where ... --> Las Vegas , where Joey appeared at ... The new video ad was filmed at the Consumer Electronics Show (CES2016) ... Wocket booth to meet and greet fans. --> ...
Breaking Biology News(10 mins):